sofosbuvir / velpatasvir

Known as: SOFOSBUVIR/VELPATASVIR 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2017-2017
012320172017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND & AIMS The fixed-dose combination of sofosbuvir/velpatasvir was highly efficacious in patients infected with genotype… (More)
  • table 2
  • table 3
  • table 5
  • table 6
  • table 7
Is this relevant?
2018
2018
BACKGROUND Chronic hepatitis C infection leads to impairment of patient-reported outcomes (PROs). Treatment with direct-acting… (More)
Is this relevant?
2018
2018
BACKGROUND & AIMS Sofosbuvir, an NS5B inhibitor, combined with velpatasvir, an NS5A inhibitor (SOF/VEL), produces high sustained… (More)
Is this relevant?
2018
2018
BACKGROUND & AIMS In phase 3 trials and real-world settings, lower proportions of patients with genotype 3 hepatitis C virus (HCV… (More)
Is this relevant?
Review
2018
Review
2018
INTRODUCTION Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease… (More)
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Hepatitis C virus (HCV) infects nearly 170 million people worldwide and is a leading cause of progressive liver… (More)
Is this relevant?
Review
2017
Review
2017
The fixed-dose combination of sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor, and velpatasvir, a second-generation… (More)
Is this relevant?
Review
2017
Review
2017
INTRODUCTION The advent of direct-acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infection has… (More)
Is this relevant?